Literature DB >> 11686609

Combinatorial synthesis through disulfide exchange: discovery of potent psammaplin A type antibacterial agents active against methicillin-resistant Staphylococcus aureus (MRSA).

K C Nicolaou1, R Hughes, J A Pfefferkorn, S Barluenga, A J Roecker.   

Abstract

Psammaplin A is a symmetrical bromotyrosine-derived disulfide natural product isolated from the Psammaplysilla sponge, which exhibits in vitro antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA). Inspired by the structure of this marine natural product, a combinatorial scrambling strategy for the construction of heterodimeric disulfide analogues was developed and applied to the construction of a 3828-membered library starting from 88 homodimeric disulfides. These psammaplin A analogues were screened directly against various gram positive bacterial strains leading to the discovery of a series of potent antibacterial agents active against methicillin-resistant Staphylococcus aureus (MRSA). Among the most active leads derived from these studies are compounds 104, 105, 113, 115, 123, and 128. The present, catalytically-induced, disulfide exchange strategy may be extendable to other types of building blocks bearing thiol groups facilitating the construction of diverse discovery-oriented combinatorial libraries.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11686609     DOI: 10.1002/1521-3765(20011001)7:19<4280::aid-chem4280>3.0.co;2-3

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  9 in total

Review 1.  The marine bromotyrosine derivatives.

Authors:  Jiangnan Peng; Jing Li; Mark T Hamann
Journal:  Alkaloids Chem Biol       Date:  2005

2.  Perspectives from nearly five decades of total synthesis of natural products and their analogues for biology and medicine.

Authors:  K C Nicolaou; Stephan Rigol
Journal:  Nat Prod Rep       Date:  2020-04-22       Impact factor: 13.423

3.  Identification of a novel small molecule HIF-1alpha translation inhibitor.

Authors:  Takuhito Narita; Shaoman Yin; Christine F Gelin; Carlos S Moreno; Manuel Yepes; K C Nicolaou; Erwin G Van Meir
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

4.  Stereospecific total synthesis of somocystinamide A.

Authors:  Takashi L Suyama; William H Gerwick
Journal:  Org Lett       Date:  2008-09-13       Impact factor: 6.005

5.  Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives.

Authors:  Malcolm W B McCulloch; Gary S Coombs; Nikhil Banerjee; Tim S Bugni; Kendell M Cannon; Mary Kay Harper; Charles A Veltri; David M Virshup; Chris M Ireland
Journal:  Bioorg Med Chem       Date:  2008-11-05       Impact factor: 3.641

6.  Synthesis of the marine bromotyrosine psammaplin F and crystal structure of a psammaplin A analogue.

Authors:  Qianjiao Yang; Dan Liu; Deyang Sun; Sen Yang; Guodong Hu; Zuti Wu; Linxiang Zhao
Journal:  Molecules       Date:  2010-12-02       Impact factor: 4.411

Review 7.  Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.

Authors:  Brigitte Bauvois; Daniel Dauzonne
Journal:  Med Res Rev       Date:  2006-01       Impact factor: 12.944

8.  Synthesis and Biological Activity of Unsymmetrical Monoterpenylhetaryl Disulfides.

Authors:  Denis V Sudarikov; Yulia V Gyrdymova; Alexander V Borisov; Julia M Lukiyanova; Roman V Rumyantcev; Oksana G Shevchenko; Diana R Baidamshina; Nargiza D Zakarova; Airat R Kayumov; Ekaterina O Sinegubova; Alexandrina S Volobueva; Vladimir V Zarubaev; Svetlana A Rubtsova
Journal:  Molecules       Date:  2022-08-10       Impact factor: 4.927

9.  Cytotoxicity of psammaplin A from a two-sponge association may correlate with the inhibition of DNA replication.

Authors:  Yahong Jiang; Eun-Young Ahn; Seung Hee Ryu; Dong-Kyoo Kim; Jang-Su Park; Hyun Joo Yoon; Song You; Burm-Jong Lee; Dong Seok Lee; Jee H Jung
Journal:  BMC Cancer       Date:  2004-09-30       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.